PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications-Reference-Cited by-同舟云学术

PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications

Published:2021-03 Issue: Volume:136 Page:109556
ISSN:0720-048X
Container-title:European Journal of Radiology
language:en
Short-container-title:European Journal of Radiology

Author:

Morawitz J.^ORCID,Kirchner J.^ORCID,Lakes J.,Bruckmann N.M.,Mamlins E.,Hiester A.,Aissa J.,Loberg C.,Schimmöller L.^ORCID,Arsov C.,Antke C.,Albers P.,Antoch G.,Sawicki L.M.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference45 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur. J. Cancer,2018

2. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy;Stephenson;J. Natl. Cancer Inst.,2006

3. Prospective comparison of whole-body MRI and (68)Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy;Sawicki;Eur. J. Nucl. Med. Mol. Imaging,2019

4. (18)F-DCFPyL PET/CT imaging in patients with biochemical recurrence prostate cancer after primary local therapy;Mena;J. Nucl. Med.,2019

5. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?;Alipour;Ther. Adv. Med. Oncol.,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-head comparison of PSMA PET/CT and mpMRI for detecting biochemical recurrence of prostate cancer: A systematic review and meta-analysis;Current Urology;2024-09

2. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer;Cancer Imaging;2024-08-30

3. 68Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0;Diagnostics;2024-06-19

4. A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer;Nuclear Medicine Communications;2024-05-10

5. Editorial for “Added Value of [18F]PSMA‐1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management”;Journal of Magnetic Resonance Imaging;2024-05-07